Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Fineline Cube Jan 14, 2026
Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Fineline Cube Jan 14, 2026
Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
Policy / Regulatory

New Guidelines for Advanced Gastric Cancer Drug Development Released in China

Fineline Cube Feb 14, 2025

The National Medical Products Administration (NMPA) of China has published the “Guidance Principles for Clinical...

Company Drug

Bristol Myers Squibb’s Opdualag Fails to Meet Primary Endpoint in Melanoma Study

Fineline Cube Feb 14, 2025

US pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) provided an update on the RELATIVITY-098 study...

Company Drug

Hengrui’s Vunakizumab Receives NMPA Approval for nr-axSpA Treatment

Fineline Cube Feb 14, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received another clinical trial...

Company

GE Healthcare Posts 1% Annual Revenue Growth in 2024 Financials

Fineline Cube Feb 14, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) released its...

Company Drug

Betta Pharma Files for EMA Approval of ALK Inhibitor Ensartinib

Fineline Cube Feb 14, 2025

Betta Pharmaceuticals (SHE: 300558) announced the initiation of a market approval filing with the European...

Company Deals Drug

Lee Kai and Yangshun Partner on Polyvinyl Alcohol Embolization Microspheres

Fineline Cube Feb 14, 2025

Chinese companies Shanghai Lee Kai Technology Co., Ltd (Kai Medtech) and Hangzhou Yangshun Medical Technology...

Company Deals

Nanos Medical Raises Over RMB300m to Boost Otolaryngology Device Lead

Fineline Cube Feb 14, 2025

China-based Nanos Medical (Shanghai) Limited, an otolaryngology device maker, has reportedly raised over RMB300 million...

Company Drug

SciClone’s Vibativ Approved by NMPA for HABP/VABP Treatment

Fineline Cube Feb 14, 2025

China-based SciClone Pharmaceuticals Inc. announced that it has received market approval from the National Medical...

Company Deals

Trinomab’s Antitetanus mAb Injection TNM002 Approved by NMPA

Fineline Cube Feb 14, 2025

China-based Trinomab Biotech Co., Ltd has received market approval for its antitetanus toxin monoclonal antibody...

Policy / Regulatory

NMPA Releases 90th Batch of Reference Drugs for GQCE

Fineline Cube Feb 14, 2025

The National Medical Products Administration (NMPA) has released the 90th batch of reference drugs for...

Company Drug

Accropeutics Doses First Patient in AC-101 Phase Ib UC Study

Fineline Cube Feb 14, 2025

Accro Bioscience (Suzhou) limited, better known as Accropeutics, a clinical-stage biotech operating out of New...

Policy / Regulatory

China Launches Major Public Health Initiatives to Enhance Healthcare Accessibility

Fineline Cube Feb 14, 2025

In a bid to bolster public health infrastructure and improve healthcare services, China’s National Health...

Company Drug

Sanofi and J&J’s E. coli Vaccine Fails Phase III Study

Fineline Cube Feb 14, 2025

France-based Sanofi (NASDAQ: SNY) and US giant Johnson & Johnson’s (J&J, NYSE: JNJ) vaccine candidate...

Company Drug

Antengene’s Xpovio Included in Taiwan’s NHI Drug List for Myeloma Treatment

Fineline Cube Feb 14, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that its Xpovio (selinexor), the world’s first...

Company Deals

Boehringer Ingelheim Partners with ExpressionEdits on Gene Therapy Tech

Fineline Cube Feb 14, 2025

German pharmaceutical giant Boehringer Ingelheim has entered into a collaboration and licensing agreement with UK-based...

Company Drug

Merck’s Zerbaxa Approved by China’s NMPA for Complex Infections

Fineline Cube Feb 14, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that it has...

Policy / Regulatory

Hainan Unveils Biomedical New Technology Policy to Boost Medical Innovation

Fineline Cube Feb 13, 2025

In-Depth Analysis and Orientation Guide for Hainan’s Biomedical New Technology PolicyThe Hainan Provincial Health Commission,...

Company Drug

Roche’s Evrysdi Tablet Approved by FDA for Spinal Muscular Atrophy

Fineline Cube Feb 13, 2025

Swiss giant Roche (SWX: ROG) has announced that it has received marketing approval from the...

Policy / Regulatory

Shanghai’s Ambitious Plan to Revolutionize Brain-Computer Interfaces

Fineline Cube Feb 13, 2025

In-Depth Analysis and Orientation Guide for Shanghai’s Brain-Computer Interface (BCI) PolicyShanghai has unveiled a groundbreaking...

Company Drug

Pfizer’s Adcetris Gets New FDA Approval for Lymphoma Treatment

Fineline Cube Feb 13, 2025

US giant Pfizer (NYSE: PFE) has announced that it has received another indication approval from...

Posts pagination

1 … 156 157 158 … 609

Recent updates

  • NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development
  • AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
  • Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
  • WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments
  • Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Company

WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.